Le Lézard
Classified in: Health
Subjects: PET, ANW

Pups Putting on the Pounds Can Now Test For An Increased Appetite Gene with Embark


BOSTON, Dec. 11, 2019 /PRNewswire/ -- Embark Veterinary, Inc., a global leader in dog genetics, today announced the addition of Pre-Opiomelanocortin (POMC) - also known as a gene to increase appetite - to its robust list of over 170 health conditions and 35 traits tested in its Breed + Health dog DNA kit. Over 50 percent of dogs in the U.S. are considered overweight or obese, which increases the risk for conditions like Type 2 diabetes, heart disease, and cancer. Now dog owners can discover whether their dog's overeating habits are in part due to genetics or, simply, overindulging in holiday treats. Either way, owners can make informed lifestyle changes to improve the health of their dogs.

(PRNewsfoto/Embark Vet)

Discovered in 2016, researchers discovered that the POMC gene can contribute to obesity in dogs, specifically in Labrador Retrievers and Flat Coated Retrievers. A mutation of this gene has been proven to contribute to an increase in body weight, body fat percentages and food motivation and, interestingly, is at higher frequencies in Retrievers bred specifically for assistance and therapy work. Mutations in POMC  are also present in humans, and while familial cases are rare, humans with POMC mutations are more prone to obesity than others.

"While all dogs need their diet and exercise watched, dogs with the POMC mutation need to be watched more closely and their food and treat intake closely monitored," said Ryan Boyko, co-founder and CEO of Embark. "Once owners can identify the problem, they can take actionable steps to ensure their dog stays at a healthy weight."

POMC has the potential to regulate appetite and weight gain in dogs, although this isn't the only gene that can affect a dog's appetite. There are at least four different genes and mutations that can impact eating behavior in dogs. With Embark's newly added POMC screening, pet owners can understand whether they should modify their dog's lifestyle to prevent obesity by regulating smaller, more frequent meals and tracking their dog's body condition. They can also take advantage of their dog's high levels of food motivation by using treats in training.

Moving forward, all of Embark's Breed + Health Kits will include the results for POMC gene mutation. In addition, dogs who have previously been tested through Embark will be alerted if their dog is affected.

About Embark
Embark Veterinary, Inc. launched in 2015 with a mission to end preventable disease in dogs. An Embark Dog DNA Test enables pet owners to learn about their dog's breed, ancestry, health, and what diseases may be in the future ? all with a simple cheek swab. By using two times more genetic information than any other test available, the company offers the most accurate results on the market. Embark was started by two brothers, Adam and Ryan Boyko, who have a passion for scientific research and a lifelong love of dogs. Embark is an official research partner of Cornell University College of Veterinary Medicine.

Embark is the official dog DNA test of the Westminster Kennel Club Dog Show.
For further information, visit Embark's website at Embarkvet.com, or follow Embark on Facebook, Twitter, and Instagram.

SOURCE Embark Veterinary, Inc.


These press releases may also interest you

at 22:03
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

at 20:40
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

at 19:40
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

at 19:00
David J. Dykeman, co-chair of the Life Sciences & Medical...

at 18:30
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...



News published on and distributed by: